Speaking to CNBC-TV18 Govardhan Dhoot, MD, Mangalam Drugs, said that margins have improved. Revenue growth is on track and it is looking at Rs 300 crore of revenue by end of FY17. We are Hoping for a 10-15 percent growth, he said. “We are focussing on the topline.”
"We are in sync with revenue because of better yields bad realisations and strong purchasing power."Watch video for more...
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
